• Home
  • Search Results

Search Results

Open
Cancer - Lymphoma
28 studies match your search
Open

USCLC National Cutaneous Lymphoma Registry

Have you been diagnosed with s Cutaneous (skin) Lymphoma? If so this could be a good study for you to paticipate in. One of the primary goals of the USCLC is to establish a registry of patients with cutaneous lymphoma in the United States. Such a registry would collect information such as the specific cutaneous lymphoma diagnosis, stage of disease, treatments used, and response to treatments. This information will collected on an online Institutional Review Board (IRB)-approved database/registry of patients from all sites. We hope that this will allow providers to better understand this rare disease by looking at data from many patients. We hope ultimately will include all the patients with cutaneous lymphoma across the United States

Age & Gender
  • 18 years ~ 99 years
  • Male, Female, Gender Inclusive
Study Interest
  • Cancer (Lymphoma)
Open

Glofitamab with or without polatuzumab vedotin or atezolizumab for Richter's Transformation

Have you been diagnosed with Chronic Lymphocytic Leukemia (CLL) that has transformed to aggressive lymphoma called Richter's Transformation (RT)? Then you may be able to participate in this study whose purpose is to evaluate the efficacy and safety of glofitamab as monotherapy and in combination with polatuzumab vedotin or atezolizumab for participants with Richter's Transformation (RT) that has transformed from chronic lymphocytic leukemia (CLL). These are targeted immune-based therapies standardly used to treat lymphoma and/or other cancers that may also work well for RT

Age & Gender
  • 18 years ~ 99 years
  • Male, Female, Gender Inclusive
Study Interest
  • Cancer (Leukemia, Lymphoma)
Open

Get Real and Heel: Cancer and Exercise Registry Study

Are you interested in improving your physical health and wellbeing during or after cancer treatment? If so, our free 12- week exercise program might be a good fit for you! We are creating a registry of adults with a cancer diagnosis who have gone through our program.

Age & Gender
  • 18 years ~ 99 years
  • Male, Female, Gender Inclusive
Study Interest
  • Cancer (Bladder, Brain and Other Nervous System, Breast, and 19 more)
  • Wellness and Lifestyle
  • Movement
Open

Phase Ib/II Study of the Administration of T Lymphocytes Expressing the CD30 Chimeric Antigen Receptor (CAR) and CCR4 for Relapsed/Refractory CD30+ Hodgkin s Lymphoma

Do you have a type of cancer known as Relapsed Hodgkin's Lymphoma?Has your cancer come back, or not get better with the last treatment you received ? If so, you may be able to participate in a gene therapy study to see if we can use your body's own immune cells as a treatment for your HL. (Example: Do you know your blood pressure? Do you sit too much at work? If you have a desk job and higher than normal blood pressure (but are not taking blood pressure medication), you may be able to participate in a research study to find out if sitting less during the workday can lower

Age & Gender
  • 3 years ~ 17 years
  • Male, Female, Gender Inclusive
Study Interest
  • Cancer (Lymphoma)
Open

Optimizing Nutrition and Exercise in Childhood Acute Lymphoblastic Leukemia

Is your child between the ages of 8-21, newly diagnosed with Leukemia or Lymphoma, and plans to receive chemotherapy treatment? If so, you may be able to participate in a research study investigating the feasiblity of a dietary intervention during treatment.

Age & Gender
  • 8 years ~ 21 years
  • Male, Female
Study Interest
  • Cancer (Leukemia, Lymphoma)
Open

Cancer Family History in Black Families

The survey and its findings will help us understand attitudes around cancer family history and genetic testing among Black people. This information will be used to develop an educational curriculum to strive towards health equity for Black people diagnosed with or at higher risk of cancer and get Black people the best cancer care.

Age & Gender
  • 18 years ~ 99 years
  • Male, Female, Gender Inclusive
Study Interest
  • Cancer (Bladder, Brain and Other Nervous System, Breast, and 18 more)
  • Healthy Volunteer or General Population
  • Minority Health
Visit Location
100% Remote (online, phone, text)
Open

Reduced Dose of Cyclophosphamide to Prevent Graft versus Host Disease after Stem Cell Transplant

Do you have AML, ALL, or MDS, and are preparing for a stem cell transplant from an unrelated donor? If so, you might be able to take part in a study to will see if a reduced dose of a drug called cyclophosphamide will still reduce your chances of developing Graft versus Host disease, but also lower your chances of side effects from the drug.

Age & Gender
  • 18 years ~ 65 years
  • Male, Female, Gender Inclusive
Study Interest
  • Cancer (Leukemia, Lymphoma)
  • Transplant
Open

CAR-T Cells in the Treatment of Patients with B Cell Malignancies

Have you been diagnosed with a B cell disease that has returned after your previous treatment or is not responding to your current treatment? If so, you might be able to take part in a study to see if a new treatment is safe and can help treat people with B-cell diseases.

Age & Gender
  • 18 years ~ 99 years
  • Male, Female, Gender Inclusive
Study Interest
  • Cancer (Lymphoma)
Open

Testing Continuous Versus Intermittent Treatment With the Study Drug Zanubrutinib for Older Patients With Previously Untreated Mantle Cell Lymphoma [A052101]

Are you over 60 and were recently diagnosed with mantle cell lymphoma? You may be able to participate in a research study to determine whether patients who reach complete disease remission after treatment with rituximab and zanubrutinib, will remain longer in remission with or without continuous zanubrutinib treatment.

Age & Gender
  • 60 years ~ 99 years
  • Male, Female, Gender Inclusive
Study Interest
  • Cancer (Lymphoma)
Open

Tafasitamab and Rituximab for Front-Line Treatment of Post-Transplant Lymphoproliferative Disorder

Have you been diagnosed with B-cell post-transplant lymphoproliferative disorder (PTLD) after an organ transplant? Have you not yet received any type of treatment for this condition? Then you may be eligible for a study to look at the safety and effectiveness of tafasitamab and rituximab combination treatment for PTLD.

Age & Gender
  • 18 years ~ 99 years
  • Male, Female, Gender Inclusive
Study Interest
  • Blood Conditions
  • Cancer (Lymphoma)
  • Transplant
Research for Me logo

Copyright © 2013-2022 The NC TraCS Institute, the integrated home of the NIH Clinical and Translational Science Awards (CTSA) Program at UNC-CH.  This website is made possible by CTSA Grant UL1TR002489 and the National Center for Advancing Translational Sciences.

Questions?

  • This email address is being protected from spambots. You need JavaScript enabled to view it.
logo for the North Carolina Translational and Clinical Sciences Institute
logo for UNC Health
logo for UNC School of Medicine
logo for UNC Research